Hostname: page-component-6bf8c574d5-956mj Total loading time: 0 Render date: 2025-02-20T22:59:20.451Z Has data issue: false hasContentIssue false
  • English
  • Français

Standards of Medical Care: How Does an Innovative Medical Procedure Become Accepted?

Published online by Cambridge University Press:  27 April 2021

Thomas Necheles
Get access Rights & Permissions [Opens in a new window]

Extract

The question of how and when a novel medical procedure becomes accepted as standard practice has important legal implications. It may in certain situations be determinative of whether third-party reimbursement is available for such procedures. It may also affect the standard used in determining a physician’s liability for negligence. This article discusses several innovative medical procedures and the process of their acceptance by the medical community. It will be seen that none of these examples effectively delineates the process by which an innovative procedure becomes the accepted standard of care. Finally, the article suggests a system based upon consensus among recognized medical experts, and recommends that this system supplant the traditional cost-benefit analysis which is currently used to determine the accepted standard of care.

No formal mechanism currently exists for the introduction of innovative medical technologies, in contrast to the complicated procedures developed for the orderly introduction of new drugs into the marketplace.

Type
Article
Information
Law, Medicine and Healthcare , Volume 10 , Issue 1 , February 1982 , pp. 15 - 18
Copyright
Copyright © American Society of Law, Medicine and Ethics 1982

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

For a discussion of this issue, see Kapp, M.B., Prescribing Approved Drugs for Nonapproved Uses: Physicians’ Disclosure Obligations to their Patients. Law, Medicine & Health Care 9(5): 20, and Mazzucca, G.A., Prescribing Approved Drugs for Nonapproved Uses: The Pharmacist's Potential for Liability. Law, Medicine & Health Care 9(5):24 (October 1981).Google ScholarPubMed
Merrill, J.P., Successful Homotransplantation of the Human Kidney between Identical Twins. Journal of the American Medical Association 160:277 (1956).Google ScholarPubMed
Hitchings, G.H. Elion, C.B., Chemical Suppression of the Immune Response, Pharmacology Reviews 15:365 (1963); Schwartz, R. Eisner, A. Dameshek, W., The Effect of 6-Mercaptopurine on Primary and Secondary Immune Responses, Journal of Clinical Investigation 38:1394 (1959).Google ScholarPubMed
van Rood, J.J. van Leeuwen, A.J., Leukocyte Grouping: A Method and its Application. Journal of Clinical Investigation 42:1382 (1963).Google ScholarPubMed
Strauss, Welt, , eds., Diseases of the Kidney (Little, Brown & Co., Boston) (1963) at 245.Google Scholar
Mannick, J.A. Egdahl, R.H., in Diseases of the Kidney, Strauss, Welt, , eds. (Little, Brown & Co., Boston) (2d ed. 1971) at 1437.Google Scholar
Monaco, A.P., in Diseases of the Kidney, Early, Gottschalk, , eds. (Little. Brown & Co., Boston) (3rd ed. 1979) at 463.Google Scholar
42 U.S.C.A. §§426(d)-(g).Google Scholar
Austen, W.G., Editorial, Heart Transplantation After Ten Years, New England Journal of Medicine 298:682 (1978).Google Scholar
Id. at 683.Google Scholar
Leaf, A., The MGH Trustees Say No to Heart Transplantation. New England Journal of Medicine 302: 1087 (1980).Google Scholar
McFarland, W., Therapy of Hypoplastic Anemia with Bone Marrow Transplantation, Archives of Internal Medicine 108: 23 (1961).Google ScholarPubMed
Thomas, E.D., Current Status of Bone Marrow Transplantation for Aplastic Anemia and Acute Leukemia. American Journal of Clinical Pathology 72:887 (1979); Camitta, B., Bone Marrow Transplantation for Severe Aplastic Anemia in Children, American Journal of Pediatric Hematology/Oncology 2:145 (1980); Gale, R.P., Approaches to Leukemic Relapse following Bone Marrow Transplantation, Transplant Procedures 10:167(1978).Google ScholarPubMed
Id.Google Scholar
Thomas, Camitta, , supra note 13.Google Scholar
Bllomfield, C.D., Treatment of Adult Acute Nonlymphocytic Leukemia-1980, Annals of Internal Medicine 93:133 (1980).Google Scholar
Beutler, E. Blume, K.G., Letter, Annals of Internal Medicine 93:778 (1980).Google Scholar
See Bergeron, W. Geis, B.D., Candle-lighters National Newsletter 4:1 (1980) discussing Guillot v. Cherry, Civil Action 79-4371-F (E.D.La. 1979).Google Scholar
Fink, D.J., Letter, New England Journal of Medicine 304:918 (1981).Google Scholar
Knox, R.A., Heart Transplants: To Pay or not to Pay, Science 209:570 (1980).Google ScholarPubMed
Id.Google Scholar
Centerwall, B.S., Cost-Benefit Analysis and Heart Transplantation, New England Journal of Medicine 304:901 (1981).Google ScholarPubMed
See, e.g., NIH Consensus Development Panel. New England Journal of Medicine 303:831 (1980).Google Scholar